Simulations Plus, Inc.

Listed Company

SLPCIK 0001023459NasdaqNon-AcceleratedSmaller ReportingServices-Computer Integrated Systems DesignFY ends Aug 31

Period

FY 2025

Revenue

$79.18M

Net Income

$-64.72M

Total Assets

$131.94M

Equity

$124.80M

Shares Out

20.21M

Op. Cash Flow

$18.13M

Business

Simulations Plus, Inc. provides modeling, simulation, AI/ML software and scientific consulting to support drug discovery, development, clinical operations, and commercialization in the biopharma sector. Its main offerings include biosimulation software such as ADMET Predictor, GastroPlus, DILIsym, Thales, MonolixSuite, Pro-ficiency, Panorama KOL Insights, and related consulting services for PBPK, QSP, PKPD, clinical operations training, and commercialization support. The company operates through product and service functions including Services, Operations, Product and Technology, Research and Development, Sales and Marketing, and General and Administrative. It sells and distributes globally to pharmaceutical, biotech, agrochemical, cosmetics, food companies, academic institutions, regulatory agencies, and via direct sales, online channels, and international distributors.

Summary from filing dated 2025-12-01

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-08-31	FY 2024 2024-08-31	FY 2023 2023-08-31	FY 2022 2022-08-31	FY 2021 2021-08-31
Revenues	79	70	60	54	—
Total cost of revenues	33	27	12	11	—
Gross profit	46	43	48	43	36
Research and development	7	6	5	3	4
Sales and marketing	12	9	7	5	—
General and administrative	21	22	28	20	21
Impairments	77	0	500,000	—	—
Total operating expenses	117	37	39	28	25
(Loss) income from operations	−71	6	9	15	11
Other income, net	1	6	3	204,000	−168,000
(Loss) income before income taxes	−69	12	12	15	11
Income tax benefit (expense)	5	−2	−2	−3	−1
Net (loss) income	−65	10	10	12	10
Basic (in usd per share)	−3.22	0.5	0.5	0.62	0.49
Diluted (in usd per share)	−3.22	0.49	0.49	0.6	0.47
Basic (in shares)	20	20	20	20	20
Diluted (in shares)	20	20	20	21	21
Foreign currency translation adjustments	−24,000	−105,000	167,000	−265,000	−101,000
Unrealized gains (losses) on available-for-sale securities	4,000	−5,000	0	—	0
Comprehensive (loss) income	−65	10	10	12	10

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-08-31	FY 2024 2024-08-31	FY 2023 2023-08-31	FY 2022 2022-08-31	FY 2021 2021-08-31
Cash and cash equivalents	31	10	58	52	37
Accounts receivable, net of allowance for credit losses of $187 and $149	10	9	10	14	10
Prepaid income taxes	2	2	804,000	1	1
Prepaid expenses and other current assets	8	8	4	3	5
Short-term investments	2	10	58	77	87
Total current assets	52	39	130	147	139
Capitalized computer software development costs, net of accumulated amortization of $21,863 and $18,727	11	12	11	10	8
Property and equipment, net	880,000	812,000	671,000	632,000	2
Operating lease right-of-use assets	407,000	1	1	1	1
Goodwill	44	96	19	13	13
Deferred tax assets, net	5	0	1	0	—
Other assets	1	542,000	425,000	439,000	51,000
Total assets	132	197	186	188	180
Accounts payable	470,000	602,000	144,000	225,000	387,000
Accrued compensation	2	5	4	3	3
Accrued expenses	1	2	659,000	931,000	2
Contracts payable - current portion	0	2	3	0	—
Operating lease liability - current portion	206,000	475,000	442,000	461,000	382,000
Deferred revenue	3	2	3	3	651,000
Total current liabilities	7	12	12	8	12
Net deferred tax assets (liabilities)	0	2	0	1	2
Operating lease liability - net of current portion	410,000	531,000	755,000	943,000	896,000
Total liabilities	7	14	16	10	14
Commitments and contingencies - Note 5	—	—	0	0	0
Preferred stock, $0.001 par value 10,000,000 shares authorized; no shares issued and outstanding	0	0	0	0	0
Common stock, $0.001 par value; 50,000,000 shares authorized, 20,137,480 and 20,051,134 shares issued and outstanding	20,000	20,000	145	139	133
Additional paid-in capital	159	152	—	—	—
(Accumulated deficit) retained earnings	−34	30	25	40	32
Accumulated other comprehensive loss	−271,000	−251,000	−141,000	−308,000	−43,000
Total shareholders' equity	125	182	170	178	166
Total liabilities and shareholders' equity	132	197	186	188	180

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-08-31	FY 2024 2024-08-31	FY 2023 2023-08-31	FY 2022 2022-08-31	FY 2021 2021-08-31
Depreciation and amortization	8	6	4	4	4
Change in fair value of contingent consideration	−640,000	−2	680,000	283,000	486,000
Discharge of holdback obligation related to Immunetrics acquisition	−224,000	0	0	—	—
Amortization of investment discounts	−64,000	−1	−1	2	2
Stock-based compensation	6	7	5	3	3
Deferred income taxes	−5	−2	−2	−270,000	−628,000
Loss from disposal of assets	23,000	0	6,000	0	0
Currency translation adjustments	−25,000	−105,000	167,000	—	—
Accounts receivable	−581,000	3	4	−4	−2
Prepaid income taxes	420,000	−1	587,000	−379,000	−42,000
Prepaid expenses and other assets	194,000	−2	−501,000	1	−157,000
Accounts payable	−132,000	−477,000	−81,000	−162,000	39,000
Other liabilities	−3	−768,000	832,000	−1	3
Accrued income taxes	0	0	−7,000	0	0
Deferred revenue	700,000	−3	176,000	2	210,000
Net cash provided by operating activities	18	13	22	18	19
Purchases of property and equipment	−713,000	−566,000	−453,000	−819,000	−2
Purchase of short-term investments	−7	−67	−95	−101	−122
Proceeds from maturities of short-term investments	14	71	115	109	100
Proceeds from sales of investments	995,000	45	0	0	—
Issuance of promissory note	−1	0	0	—	—
Purchased intangibles	−379,000	−541,000	−601,000	0	0
Business acquisition, net of cash acquired	0	−99	−8	0	0
Net working capital & excess cash settlement - Pro-ficiency acquisition	−227,000	0	0	—	—
Capitalized computer software development costs	−3	−3	−3	−3	−3
Net cash used in investing activities	4	−54	7	4	−27
Payment of dividends	0	−5	−5	−5	−5
Payments on contracts payable	−2	−3	0	−4	—
Proceeds from the exercise of stock options	430,000	731,000	2	891,000	1
Repurchase and retirement of common shares	0	0	−20	0	0
Net cash used in financing activities	−1	−7	−23	−8	−5
Net increase (decrease) in cash and cash equivalents	21	−47	6	—	—
Income taxes paid	1	6	3	3	2
Measurement period adjustments (See Note 2)	956,000	0	0	—	—
Creation of contract liabilities from acquisition of subsidiaries	0	0	6	0	0
Right of use assets capitalized	426,000	212,000	227,000	624,000	905,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro